The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
Open accessAbstract
AIMS: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Translational cell and animal models provided concept proofs and a delayed-start (DS) treatment paradigm, the basis for preliminary clinical assessments. RESULTS: For translational studies, we assessed the effect of oxidative insults in mice systemically prechelated with deferiprone (DFP) by following motor functions, striatal dopamine (HPLC and MRI-PET), and brain iron deposition (relaxation-R2*-MRI) aided by spectroscopic measurements of neuronal labile iron (with fluorescence-sensitive iron sensors) and oxidative damage by markers of protein, lipid, and DNA modification. DFP significantly reduced labile iron and biological damage in oxidation-stressed cells and animals, improving motor functions while raising striatal dopamine. For a pilot, double-blind, placebo-controlled randomized clinical trial, early-stage Parkinson's patients on stabilized dopamine regimens enrolled in a 12-month single-center study with DFP (30 mg/kg/day). Based on a 6-month DS paradigm, early-start patients (n=19) compared to DS patients (n=18) (37/40 completed) responded significantly earlier and sustainably to treatment in both substantia nigra iron deposits (R2* MRI) and Unified Parkinson's Disease Rating Scale motor indicators of disease progression (p<0.03 and p<0.04, respectively). Apart from three rapidly resolved neutropenia cases, safety was maintained throughout the trial. INNOVATION: A moderate iron chelation regimen that avoids changes in systemic iron levels may constitute a novel therapeutic modality for PD. CONCLUSIONS: The therapeutic features of a chelation modality established in translational models and in pilot clinical trials warrant comprehensive evaluation of symptomatic and/or disease-modifying potential of chelation in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals in biology and medicine
(1991) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(91)90478-o · Cited by 17,178
Oxidative stress and neurodegeneration: where are we now?
Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Increased nigral iron content in postmortem parkinsonian brain
Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91361-4 · Cited by 963
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1
Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P. T., & Surmeier, D. J. (2010) · Nature · doi:10.1038/nature09536 · Cited by 843
Petronilli, V., Miotto, G., Canton, M., Brini, M., Colonna, R., Bernardi, P., & Di Lisa, F. (1999) · Biophysical Journal · doi:10.1016/s0006-3495(99)77239-5 · Cited by 675
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Iron Overload in Human Disease
Fleming, R. E., & Ponka, P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1004967 · Cited by 587
Iron metabolism in the CNS: implications for neurodegenerative diseases
Rouault, T. A. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3453 · Cited by 496
Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains
Connor, J. R., Menzies, S. L., Martin, S. M. S., & Mufson, E. J. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490270421 · Cited by 472
Free radicals in biology and medicine
Rice-Evans, C. (1985) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(85)90074-x · Cited by 472
Regulation of iron acquisition and storage: consequences for iron-linked disorders
De Domenico, I., McVey Ward, D., & Kaplan, J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2295 · Cited by 464 · cited 1×
“I ron metabolism is a tightly regulated process that is designed to render iron available for biochemical functions (11, 56) while minimizing the metal’s involvement in harmful radical formation (29).”
Selective iron chelation in Friedreich ataxia: biologic and clinical implications
Boddaert, N., Le Quan Sang, K. H., Rötig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.-C., Munnich, A., & Cabantchik, Z. I. (2007) · Blood · doi:10.1182/blood-2006-12-065433 · Cited by 409
Self-citationMagnetic resonance imaging markers of Parkinson's disease nigrostriatal signature
Péran, P., Cherubini, A., Assogna, F., Piras, F., Quattrocchi, C., Peppe, A., Celsis, P., Rascol, O., Démonet, J.-F., Stefani, A., et al. (2010) · Brain · doi:10.1093/brain/awq212 · Cited by 399
Iron misregulation in the brain: a primary cause of neurodegenerative disorders
Ke, Y., & Qian, Z. M. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00353-3 · Cited by 340
Rapid, complete and large‐scale generation of post‐mitotic neurons from the human LUHMES cell line
Scholz, D., Pöltl, D., Genewsky, A., Weng, M., Waldmann, T., Schildknecht, S., & Leist, M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07255.x · Cited by 337
Self-citationSafety and effectiveness of long-term therapy with the oral iron chelator deferiprone
Cohen, A. R., Galanello, R., Piga, A., De Sanctis, V., & Tricta, F. (2003) · Blood · doi:10.1182/blood-2002-10-3280 · Cited by 323
Glutathione—a review on its role and significance in Parkinson's disease
Martin, H. L., & Teismann, P. (2009) · The FASEB Journal · doi:10.1096/fj.08-125443 · Cited by 314
The possible role of iron in the etiopathology of parkinson's disease
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. (1993) · Movement Disorders · doi:10.1002/mds.870080102 · Cited by 301
Przedborski, S., & Vila, M. (2003) · PubMed · Cited by 286
PRZEDBORSKI, S., & VILA, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07476.x · Cited by 283
Zheng, H., Weiner, L. M., Bar-Am, O., Epsztejn, S., Cabantchik, Z. I., Warshawsky, A., Youdim, M. B. H., & Fridkin, M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.10.037 · Cited by 278
Self-citationGlickstein, H., Ben El, R., Shvartsman, M., & Cabantchik, Z. I. (2005) · Blood · doi:10.1182/blood-2005-02-0460 · Cited by 249
Self-citationProfile of altered brain iron acquisition in restless legs syndrome
Connor, J. R., Ponnuru, P., Wang, X.-S., Patton, S. M., Allen, R. P., & Earley, C. J. (2011) · Brain · doi:10.1093/brain/awr012 · Cited by 243
A Review of Fluorescence Methods for Assessing Labile Iron in Cells and Biological Fluids
Espósito, B. P., Epsztejn, S., Breuer, W., & Cabantchik, Z. I. (2002) · Analytical Biochemistry · doi:10.1006/abio.2002.5611 · Cited by 241
Self-citationMagnetic resonance imaging measurement of iron overload
Wood, J. C. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3280d2b76b · Cited by 241
Rascol, O., Fitzer-Attas, C. J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W., Melamed, E., Poewe, W., Stocchi, F., Tolosa, E., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70073-4 · Cited by 212
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
Schapira, A. H., McDermott, M. P., Barone, P., Comella, C. L., Albrecht, S., Hsu, H. H., Massey, D. H., Mizuno, Y., Poewe, W., Rascol, O., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70117-0 · Cited by 203
Mitochondrial iron metabolism and its role in neurodegeneration
Horowitz, M. P., & Greenamyre, J. T. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100354 · Cited by 195
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
Schapira, A. H. V., & Obeso, J. (2006) · Annals of Neurology · doi:10.1002/ana.20789 · Cited by 177
Breuer, W., Shvartsman, M., & Cabantchik, Z. I. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.010 · Cited by 175 · cited 3×
“However, the biological damage associated with siderosis mostly results from a rise in labile iron, which is composed of redox-active and chelatable forms of the metal (5).”
Self-citationRedistribution of accumulated cell iron: a modality of chelation with therapeutic implications
Sohn, Y.-S., Breuer, W., Munnich, A., & Cabantchik, Z. I. (2008) · Blood · doi:10.1182/blood-2007-07-102335 · Cited by 167
Self-citationKoorts, A. M., & Viljoen, M. (2007) · Archives of Physiology and Biochemistry · doi:10.1080/13813450701318583 · Cited by 164
Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease
Du, G., Lewis, M. M., Styner, M., Shaffer, M. L., Sen, S., Yang, Q. X., & Huang, X. (2011) · Movement Disorders · doi:10.1002/mds.23643 · Cited by 162
MRI assessment of basal ganglia iron deposition in Parkinson's disease
Wallis, L. I., Paley, M. N. J., Graham, J. M., Grünewald, R. A., Wignall, E. L., Joy, H. M., & Griffiths, P. D. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21563 · Cited by 161
Oxidation Chemistry of Catecholamines and Neuronal Degeneration: An Update
Napolitano, A., Manini, P., & d’Ischia, M. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795496863 · Cited by 153
Montuschi, P., Paris, D., Melck, D. J., Lucidi, V., Ciabattoni, G., Raia, V., Calabrese, C., Bush, A., Barnes, P. J., & Motta, A. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200072 · Cited by 152
Garçon, G., Dagher, Z., Zerimech, F., Ledoux, F., Courcot, D., Aboukaïs, A., Puskaric, E., & Shirali, P. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.09.012 · Cited by 148
Self-citationCombined Therapy with Idebenone and Deferiprone in Patients with Friedreich’s Ataxia
Velasco‐Sanchez, D., Aracil, A., Montero, R., Mas, A., Jiménez, L., O’Callaghan, M., Tondo, M., Capdevila, A., Blanch, J., Artuch, R., et al. (2010) · The Cerebellum · doi:10.1007/s12311-010-0212-7 · Cited by 147
Iron Regulatory Proteins: From Molecular Mechanisms to Drug Development
Recalcati, S., Minotti, G., & Cairo, G. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2983 · Cited by 141
Dexter, D. T., Statton, S. A., Whitmore, C. L., Freinbichler, W., Weinberger, P., Tipton, K. F., Corte, L., Ward, R. J., & Crichton, R. R. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0531-3 · Cited by 139
Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease
Chen, C., Liu, J., Wu, Y., Chen, Y., Cheng, H., Cheng, M., & Chiu, D. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.11.011 · Cited by 136
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation
Abbruzzese, G., Cossu, G., Balocco, M., Marchese, R., Murgia, D., Melis, M., Galanello, R., Barella, S., Matta, G., Ruffinengo, U., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.043018 · Cited by 134
H‐ferritin is the major source of iron for oligodendrocytes
Todorich, B., Zhang, X., & Connor, J. R. (2011) · Glia · doi:10.1002/glia.21164 · Cited by 130
Relaxation induced by ferritin: a better understanding for an improved MRI iron quantification
Gossuin, Y., Müller, R. N., & Gillis, P. (2004) · NMR in Biomedicine · doi:10.1002/nbm.903 · Cited by 117
Lee, D. W., Rajagopalan, S., Siddiq, A., Gwiazda, R. H., Yang, L., Beal, M. F., Ratan, R. R., & Andersen, J. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000638 · Cited by 108
Mitochondrial Mayhem: The Mitochondrion as a Modulator of Iron Metabolism and Its Role in Disease
Huang, M. L.-H., Lane, D. J. R., & Richardson, D. R. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3921 · Cited by 103
Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia
Whitnall, M., Rahmanto, Y. S., Huang, M., Saletta, F., Lok, H. C., Gutiérrez, L., Lázaro, F. J., Fleming, A. J., Pierre, T. G. S., Mikhael, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215349109 · Cited by 100
Garçon, G., Leleu, B., Marez, T., Zerimech, F., Haguenoer, J., Furon, D., & Shirali, P. (2007) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2007.02.002 · Cited by 96
Self-citationNeuroprotective actions of deferiprone in cultured cortical neurones and SHSY‐5Y cells
Molina‐Holgado, F., Gaeta, A., Francis, P. T., Williams, R. J., & Hider, R. C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05332.x · Cited by 90
Chelators in the Treatment of Iron Accumulation in Parkinson's Disease
Mounsey, R. B., & Teismann, P. (2012) · International Journal of Cell Biology · doi:10.1155/2012/983245 · Cited by 89
Anemia or low hemoglobin levels preceding Parkinson disease: A case-control study
Savica, R., Grossardt, B. R., Carlin, J. M., Icen, M., Bower, J. H., Ahlskog, J. E., Maraganore, D. M., Steensma, D. P., & Rocca, W. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd80c1 · Cited by 87
The potential application of iron chelators for the treatment of neurodegenerative diseases
Hider, R. C., Roy, S., Ma, Y. M., Kong, X. L., & Preston, J. E. (2011) · Metallomics · doi:10.1039/c0mt00087f · Cited by 87
Chelating Agents for the Treatment of Systemic Iron Overload
Ma, Y., Zhou, T., Kong, X. L., & Hider, R. C. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800609724 · Cited by 87
Weinreb, O., Amit, T., Mandel, S. A., Kupershmidt, L., & Youdim, M. B. H. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2929 · Cited by 83
Iron chelation and neuroprotection in neurodegenerative diseases
Li, X., Jankovic, J. J., & Le, W. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0518-0 · Cited by 78
Shvartsman, M., Kikkeri, R. V., Shanzer, A., & Cabantchik, Z. I. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00054.2007 · Cited by 78
Self-citationIron Metabolism and Mitochondrial Abnormalities in Friedreich Ataxia
Pandolfo, M. (2002) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2002.0591 · Cited by 71
Febbraro, F., Andersen, K. J., Sánchez-Guajardo, V., Tentillier, N., & Romero‐Ramos, M. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.03.017 · Cited by 70
Pennell, D. J., Carpenter, J., Roughton, M., & Cabantchik, Z. I. (2011) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-13-45 · Cited by 64
Self-citationDeferiprone Chelation Therapy for Thalassemia Major
Galanello, R., & Campus, S. (2009) · Acta Haematologica · doi:10.1159/000243800 · Cited by 61
Ohata, H., Chacon, E., Tesfai, S. A., Harper, I. S., Herman, B. A., & Lemasters, J. J. (1998) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1020588618496 · Cited by 53
Kakhlon, O., Breuer, W. V., Münnich, A., & Cabantchik, Z. I. (2010) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y09-128 · Cited by 52
Self-citationLaloux, C., Pétrault, M., Lecointe, C., Devos, D., & Bordet, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.02.008 · Cited by 51
Self-citationWaldmeier, P. C., Buchle, A.-M., & Steulet, A.-F. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90222-i · Cited by 51
X‐ray fluorescence analysis of iron and manganese distribution in primary dopaminergic neurons
Dučić, T., Barski, E., Salome-Pateyron, M., Koch, J. C., Bähr, M., & Lingor, P. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12073 · Cited by 50
Study of brain anatomy with high-field MRI: recent progress
Duyn, J. H. (2010) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2010.02.007 · Cited by 50
Olanow, C. W., & Youdim, M. B. H. (1996) · Elsevier eBooks · doi:10.1016/b978-012525445-8/50006-0 · Cited by 50
Targeting Mitochondria for Neuroprotection in Parkinson's Disease
Schapira, A. H. V. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4419 · Cited by 48
Chen, B. T., Avshalumov, M. V., & Rice, M. E. (2002) · Journal of Neurophysiology · doi:10.1152/jn.00629.2001 · Cited by 46
Garçon, G., Shirali, P., Garry, S., Fontaine, M., Zerimech, F., Martin-Ponthieu, A., & Hannothiaux, M.-H. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(00)00231-9 · Cited by 37
Self-citationRescuing iron‐overloaded macrophages by conservative relocation of the accumulated metal
Sohn, Y., Mitterstiller, A., Breuer, W. V., Weiß, G., & Cabantchik, Z. I. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01120.x · Cited by 36
Self-citationIncreased sensitivity of striatal dopamine release to H2O2 upon chronic rotenone treatment
Milusheva, E., Baranyi, M., Kittel, Á., Sperlágh, B., & Vizi, E. S. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.02.034 · Cited by 36
Bonda, D., Smith, M. A., Perry, G. L., Lee, H., Wang, X., & Zhu, X. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072562 · Cited by 36
Gröger, A., & Berg, D. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0873-0 · Cited by 34
Hows, M. E. P., Ashmeade, T. E., Billinton, A., Perren, M. J., Austin, A., Virley, D. J., Organ, A. J., & Shah, A. J. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.02.011 · Cited by 25
Cited by
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695
Ferroptosis: mechanisms, biology and role in disease
Jiang, X., Stockwell, B. R., & Conrad, M. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00324-8 · Cited by 7,505
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
Role of GPX4 in ferroptosis and its pharmacological implication
Seibt, T. M., Proneth, B., & Conrad, M. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.014 · Cited by 1,520
Ferroptosis: Mechanisms and links with diseases
Yan, H.-F., Zou, T., Tuo, Q.-Z., Xu, S., Li, H., Belaidi, A. A., & Lei, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00428-9 · Cited by 1,471
“Similarly, DFP has reported beneficial effects for PD patients in phase II studies.(221,222) The loss of ceruloplasmin (Cp), a protein responsible for iron export, is also associated with iron-dependent parkinsonism in mice,(223) and in the cerebrospinal fluid (CSF) of PD patients.”
Metadata
- Authors
- Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., Duhamel, A., Jissendi, P., Dujardin, K., Auger, F., Ravasi, L., Hopes, L., Grolez, G., Firdaus, W., Sablonnière, B., Strubi-Vuillaume, I., Zahr, N., Destée, A., Corvol, J.-C., Pöltl, D., Leist, M., Rose, C., Defebvre, L., Marchetti, P., Cabantchik, Z. I., & Bordet, R.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2014-07-10
- Volume
- 21
- Issue
- 2
- Pages
- 195-210
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2004628001
- Cited by
- 619
- References
- 77
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.